2.50
Hdl Handle:
http://hdl.handle.net/2336/46904
Title:
Screening and prevention of diabetic blindness
Authors:
Stefansson, E; Bek, T; Porta, M; Larsen, N; Kristinsson, J K; Agardh, E
Citation:
Acta Ophthalmol Scand. 2000, 78(4):374-85
Issue Date:
1-Aug-2000
Abstract:
Diabetic eye disease remains a major cause of blindness in the world. Laser treatment for proliferative diabetic retinopathy and diabetic macular edema became available more than two decades ago. The outcome of treatment depends on the timing of laser treatment. The laser treatment is optimally delivered when high-risk characteristics have developed in proliferative retinopathy or diabetic macular edema and before this has significantly affected vision. Laser treatment is usually successful if applied during this optimal period whereas the treatment benefit falls sharply if the treatment is applied too late. In order to optimize the timing of laser treatment in diabetic eye disease screening programs have been established. The oldest screening program is 20 years old and several programs have been established during the last decade. In this paper the organisation and methods of screening programs are described including direct and photographic screening. The incidence and prevalence of blindness is much lower in populations where screening for diabetic eye disease has been established compared to diabetic populations without screening. Technical advantages may allow increased efficiency and telescreening. From a public health standpoint screening for diabetic eye disease is one of the most cost effective health procedures available. Diabetic eye disease can be prevented using existing technology and the cost involved is many times less than the cost of diabetic blindness.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://dx.doi.org/10.1034/j.1600-0420.2000.078004374.x

Full metadata record

DC FieldValue Language
dc.contributor.authorStefansson, E-
dc.contributor.authorBek, T-
dc.contributor.authorPorta, M-
dc.contributor.authorLarsen, N-
dc.contributor.authorKristinsson, J K-
dc.contributor.authorAgardh, E-
dc.date.accessioned2008-12-23T12:11:08Z-
dc.date.available2008-12-23T12:11:08Z-
dc.date.issued2000-08-01-
dc.date.submitted2008-12-23-
dc.identifier.citationActa Ophthalmol Scand. 2000, 78(4):374-85en
dc.identifier.issn1395-3907-
dc.identifier.pmid10990036-
dc.identifier.doi10.1034/j.1600-0420.2000.078004374.x-
dc.identifier.urihttp://hdl.handle.net/2336/46904-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractDiabetic eye disease remains a major cause of blindness in the world. Laser treatment for proliferative diabetic retinopathy and diabetic macular edema became available more than two decades ago. The outcome of treatment depends on the timing of laser treatment. The laser treatment is optimally delivered when high-risk characteristics have developed in proliferative retinopathy or diabetic macular edema and before this has significantly affected vision. Laser treatment is usually successful if applied during this optimal period whereas the treatment benefit falls sharply if the treatment is applied too late. In order to optimize the timing of laser treatment in diabetic eye disease screening programs have been established. The oldest screening program is 20 years old and several programs have been established during the last decade. In this paper the organisation and methods of screening programs are described including direct and photographic screening. The incidence and prevalence of blindness is much lower in populations where screening for diabetic eye disease has been established compared to diabetic populations without screening. Technical advantages may allow increased efficiency and telescreening. From a public health standpoint screening for diabetic eye disease is one of the most cost effective health procedures available. Diabetic eye disease can be prevented using existing technology and the cost involved is many times less than the cost of diabetic blindness.en
dc.language.isoenen
dc.publisherBlackwellen
dc.relation.urlhttp://dx.doi.org/10.1034/j.1600-0420.2000.078004374.xen
dc.subject.meshBlindnessen
dc.subject.meshDiabetes Complicationsen
dc.subject.meshDiabetic Retinopathyen
dc.subject.meshEconomics, Medicalen
dc.subject.meshEuropeen
dc.subject.meshHumansen
dc.subject.meshIncidenceen
dc.subject.meshLaser Coagulationen
dc.subject.meshPrevalenceen
dc.subject.meshPreventive Medicineen
dc.subject.meshVision Screeningen
dc.subject.meshWisconsinen
dc.titleScreening and prevention of diabetic blindnessen
dc.typeArticleen
dc.contributor.departmentDept. of Ophthalmology, University of Iceland, Landspitalinn, Reykjavik. einarste@rsp.isen
dc.identifier.journalActa ophthalmologica Scandinavicaen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.